These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

396 related items for PubMed ID: 17944584

  • 41. Switching from calcium carbonate to sevelamer hydrochloride has suppressive effects on the progression of aortic calcification in hemodialysis patients: assessment using plain chest X-ray films.
    Izumi M, Morita S, Nishian Y, Miyamoto T, Kasumoto H, Oue M, Hori K, Kitamura R, Yamamoto S, Nakanishi T.
    Ren Fail; 2008; 30(10):952-8. PubMed ID: 19016145
    [Abstract] [Full Text] [Related]

  • 42. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer.
    Russo D, Miranda I, Ruocco C, Battaglia Y, Buonanno E, Manzi S, Russo L, Scafarto A, Andreucci VE.
    Kidney Int; 2007 Nov; 72(10):1255-61. PubMed ID: 17805238
    [Abstract] [Full Text] [Related]

  • 43. Sevelamer decreases systemic inflammation in parallel to a reduction in endotoxemia.
    Stinghen AE, Gonçalves SM, Bucharles S, Branco FS, Gruber B, Hauser AB, Pecoits-Filho R.
    Blood Purif; 2010 Nov; 29(4):352-6. PubMed ID: 20357435
    [Abstract] [Full Text] [Related]

  • 44. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients.
    Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, Burke SK.
    Kidney Int; 2007 Nov; 72(9):1130-7. PubMed ID: 17728707
    [Abstract] [Full Text] [Related]

  • 45. Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom.
    Thompson M, Bartko-Winters S, Bernard L, Fenton A, Hutchison C, Di Iorio B.
    J Med Econ; 2013 Nov; 16(6):744-55. PubMed ID: 23550810
    [Abstract] [Full Text] [Related]

  • 46. Blockage of the renin-angiotensin system attenuates mortality but not vascular calcification in uremic rats: sevelamer carbonate prevents vascular calcification.
    Tokumoto M, Mizobuchi M, Finch JL, Nakamura H, Martin DR, Slatopolsky E.
    Am J Nephrol; 2009 Nov; 29(6):582-91. PubMed ID: 19145073
    [Abstract] [Full Text] [Related]

  • 47. Impact of non-traditional phosphate binders and cinacalcet on haemodialysis patient biochemistry, pill burden and cost.
    Gray NA, Krishnasamy R, Vardesh DL, Hollett PR, Anstey CM.
    Nephrology (Carlton); 2011 Nov; 16(8):688-96. PubMed ID: 21649793
    [Abstract] [Full Text] [Related]

  • 48. Sevelamer hydrochloride use and circulating endotoxin in hemodialysis patients: a pilot cross-sectional study.
    Sun PP, Perianayagam MC, Jaber BL.
    J Ren Nutr; 2009 Sep; 19(5):432-8. PubMed ID: 19464926
    [Abstract] [Full Text] [Related]

  • 49. [Management of hyperphosphatemia ; phosphate-binder].
    Yokoyama K.
    Clin Calcium; 2009 Feb; 19(2):205-12. PubMed ID: 19182360
    [Abstract] [Full Text] [Related]

  • 50. New strategy to attenuate pulse wave velocity in haemodialysis patients.
    Takenaka T, Suzuki H.
    Nephrol Dial Transplant; 2005 Apr; 20(4):811-6. PubMed ID: 15772266
    [Abstract] [Full Text] [Related]

  • 51. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density.
    Asmus HG, Braun J, Krause R, Brunkhorst R, Holzer H, Schulz W, Neumayer HH, Raggi P, Bommer J.
    Nephrol Dial Transplant; 2005 Aug; 20(8):1653-61. PubMed ID: 15930018
    [Abstract] [Full Text] [Related]

  • 52. Pharmacology of the phosphate binder, lanthanum carbonate.
    Damment SJ.
    Ren Fail; 2011 Aug; 33(2):217-24. PubMed ID: 21332344
    [Abstract] [Full Text] [Related]

  • 53. Potential for bilateral nephrectomy to reduce oxalate release after combined liver and kidney transplantation for primary hyperoxaluria type 1.
    Mizusawa Y, Parnham AP, Falk MC, Burke JR, Nicol D, Yamanaka J, Lynch SV, Strong RW.
    Clin Transplant; 1997 Oct; 11(5 Pt 1):361-5. PubMed ID: 9361924
    [Abstract] [Full Text] [Related]

  • 54. Lanthanum: new drug. Hyperphosphataemia in dialysis patients: more potential problems than benefits.
    Prescrire Int; 2007 Apr; 16(88):47-50. PubMed ID: 17458039
    [Abstract] [Full Text] [Related]

  • 55. Sevelamer hydrochloride reverses parathyroid gland enlargement via regression of cell hypertrophy but not apoptosis in rats with chronic renal insufficiency.
    Nagano N, Miyata S, Abe M, Wakita S, Kobayashi N, Wada M.
    Nephrol Dial Transplant; 2006 Mar; 21(3):634-43. PubMed ID: 16169864
    [Abstract] [Full Text] [Related]

  • 56. [Phosphorus (P) chelant in dialysis: efficacy and cost. Peritoneal dialysis solutions].
    Montenegro J.
    Nefrologia; 2008 Mar; 28 Suppl 5():53-7. PubMed ID: 18847421
    [Abstract] [Full Text] [Related]

  • 57. Effect of dietary changes on urinary oxalate excretion and calcium oxalate supersaturation in patients with hyperoxaluric stone formation.
    Penniston KL, Nakada SY.
    Urology; 2009 Mar; 73(3):484-9. PubMed ID: 19118878
    [Abstract] [Full Text] [Related]

  • 58. Effects of calcium supplements on the risk of renal stone formation in a population with low oxalate intake.
    Stitchantrakul W, Sopassathit W, Prapaipanich S, Domrongkitchaiporn S.
    Southeast Asian J Trop Med Public Health; 2004 Dec; 35(4):1028-33. PubMed ID: 15916110
    [Abstract] [Full Text] [Related]

  • 59. Differences in gastrointestinal calcium absorption after the ingestion of calcium-free phosphate binders.
    Behets GJ, Dams G, Damment SJ, Martin P, De Broe ME, D'Haese PC.
    Am J Physiol Renal Physiol; 2014 Jan 01; 306(1):F61-7. PubMed ID: 24197066
    [Abstract] [Full Text] [Related]

  • 60. Sevelamer hydrochloride exacerbates metabolic acidosis in hemodialysis patients, depending on the dosage.
    Oka Y, Miyazaki M, Takatsu S, Kunitomo K, Uno F, Maruyama M, Matsuda H.
    Ther Apher Dial; 2007 Apr 01; 11(2):107-13. PubMed ID: 17381531
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.